OTCMKTS:MAYNF Mayne Pharma Group (MAYNF) Stock Price, News & Analysis → Beta testers blew this thing up (From Prosper Trading Academy) (Ad) Free MAYNF Stock Alerts $3.27 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$3.27▼$3.2750-Day Range$3.27▼$4.5452-Week Range$1.90▼$4.59VolumeN/AAverage Volume1,156 shsMarket CapitalizationN/AP/E Ratio90.69Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Mayne Pharma Group alerts: Email Address Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Mayne Pharma Group Stock (OTCMKTS:MAYNF)Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.Read More MAYNF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MAYNF Stock News HeadlinesMay 12, 2024 | finance.yahoo.comMayne Pharma Group Limited's (ASX:MYX) largest shareholders are individual investors with 38% ownership, institutions own 33%April 23, 2024 | afr.comMayne Pharma Group LimitedFebruary 28, 2024 | seekingalpha.comMayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comMayne Pharma Group Limited (MAYNF)February 27, 2024 | msn.comMayne Pharma Group reports 1H resultsDecember 29, 2023 | finance.yahoo.comMayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Mayne Pharma Group (OtherMAYNF) and Biogen (BIIB)November 18, 2023 | finance.yahoo.comWhile institutions invested in Mayne Pharma Group Limited (ASX:MYX) benefited from last week's 12% gain, retail investors stood to gain the mostOctober 28, 2023 | finance.yahoo.comShawn O’Brien Buys Handful Of Shares In Mayne Pharma GroupOctober 23, 2023 | finance.yahoo.comStrong week for Mayne Pharma Group (ASX:MYX) shareholders doesn't alleviate pain of five-year lossSeptember 1, 2023 | finance.yahoo.comMayne Pharma Group Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagJune 13, 2023 | markets.businessinsider.comWilsons Sticks to Its Buy Rating for Mayne Pharma Group (MAYNF)May 16, 2023 | afr.comInfomedia wrangler Viburnum butts heads with Mayne Pharma’s boardApril 18, 2023 | finance.yahoo.comThere's No Escaping Mayne Pharma Group Limited's (ASX:MYX) Muted RevenuesMarch 1, 2023 | finance.yahoo.comMayne Pharma Group Limited (ASX:MYX) Shares Could Be 49% Below Their Intrinsic Value EstimateFebruary 27, 2023 | finance.yahoo.comDr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription DealFebruary 27, 2023 | msn.comDr Reddy's Laboratories announces agreement to acquire Mayne Pharma’s U.S. generic prescription product portfolioFebruary 27, 2023 | msn.comDr. Reddy’s Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolioJanuary 31, 2023 | seekingalpha.comMAYND Mayne Pharma Group LimitedDecember 7, 2022 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Lantheus (LNTH) and Mayne Pharma Group Limited (OtherMAYNF)December 5, 2022 | seekingalpha.comTherapeuticsMD enters agreements to license products to Mayne PharmaDecember 2, 2022 | finance.yahoo.comMayne Pharma Group Limited (ASX:MYX) Analysts Just Trimmed Their Revenue Forecasts By 19%November 9, 2022 | finance.yahoo.comMayne Pharma Group (ASX:MYX) investors are sitting on a loss of 54% if they invested five years agoSeptember 13, 2022 | fool.com.auIs the Mayne Pharma Group Ltd share price in the buy zone after today’s news?August 31, 2022 | finance.yahoo.comAnalysts Are More Bearish On Mayne Pharma Group Limited (ASX:MYX) Than They Used To BeSee More Headlines Receive MAYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mayne Pharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:MAYNF CUSIPN/A CIKN/A Webwww.maynepharma.com Phone(188) 209-2666FaxN/AEmployees780Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio90.69 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Shawn Patrick O'Brien B.Sc (Age 65)CEO, MD & Director Comp: $828.48kMr. Aaron GrayChief Financial OfficerMs. Kimberly Parker J.D.Executive VP & General CounselMr. Brant Schofield (Age 58)Executive Vice President of Corporate Development Comp: $677.7kMs. Erinn NathanielDirector of Global Human ResourcesMr. Daniel MooreExecutive Vice President of CommercialDr. Frank Casty M.D.Executive VP & Global Chief Medical OfficerMr. Brenton WalterFinancial ControllerMs. Laura LoftusAssociate General Counsel & Company SecretaryMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFJCR PharmaceuticalsOTCMKTS:JCRRFKyowa KirinOTCMKTS:KYKOFView All Competitors MAYNF Stock Analysis - Frequently Asked Questions How have MAYNF shares performed in 2024? Mayne Pharma Group's stock was trading at $4.25 at the beginning of the year. Since then, MAYNF stock has decreased by 23.2% and is now trading at $3.2650. View the best growth stocks for 2024 here. Are investors shorting Mayne Pharma Group? Mayne Pharma Group saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 100 shares, a drop of 75.0% from the May 15th total of 400 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is presently 0.5 days. View Mayne Pharma Group's Short Interest. When did Mayne Pharma Group's stock split? Shares of Mayne Pharma Group reverse split before market open on Wednesday, January 18th 2023. The 1-20 reverse split was announced on Wednesday, January 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Mayne Pharma Group? Shares of MAYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MAYNF) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mayne Pharma Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mayne Pharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.